Novo Nordisk cuts its 2025 profit outlook again

Novo Nordisk, the maker of the semaglutide drugs Ozempic, Wegovy and Rybelsus, lowered its full-year 2025 operating profit growth guidance to 10% to 16% at constant exchange rates, down from the 16% to 24% range the company set in May ^[1]. It was the second cut of the year, and it was not the last.

BioSpace, reporting on Novo's later restructuring, points back to a company release titled "Novo Nordisk lowers sales and operating profit outlook for 2025" dated July 29, 2025, as the source of that 10% to 16% figure, and notes that the target "had already been lowered" from the 16% to 24% range set in May ^[1]. In other words, by midsummer the company had roughly halved the top end of what it expected to earn in growth terms this year.

A third cut followed in September

On September 10, 2025, Novo Nordisk announced it was cutting about 9,000 jobs worldwide — an 11% headcount reduction, according to BMO Capital Markets — to generate around $1.25 billion in annualized savings through 2026 ^[1]. The company employs 78,400 people, and about 5,000 of the affected positions are in Denmark ^[1]. The layoffs began "immediately," and Novo said it would take 9 billion Danish kroner (about $1.41 billion) in one-off impairment and severance charges in its third-quarter 2025 results, partly offset by 1 billion kroner (roughly $160 million) in fourth-quarter savings ^[1].

With that announcement came the third guidance cut: operating profit growth of 4% to 10% at constant currencies, down from 10% to 16% ^[1]. Novo said the change reflected a "one-off negative impact of around 6 percentage points" and emphasized that the adjustment "only factors in the one-off restructuring costs" tied to the layoffs ^[1].

The company framed the cuts as a way to "simplify" its business and "improve the speed of decision-making," with savings "redirected to growth opportunities in diabetes and obesity," focused on commercial execution and research and development ^[1]. New CEO Maziar Mike Doustdar said the move would build an "increased performance-based culture" and help the company prioritize "investment where it will have the most impact." He added: "Our markets are evolving. Our company must evolve as well" ^[1]. On the second-quarter earnings call the month before, Doustdar had told investors, "we need to reallocate and look at our cost base and really put the money where the growth is" ^[1].

Analysts were blunt about how Novo got here. With shares down about 37% year to date, BMO wrote, "a significant shift was the only option," citing "underinvestment in manufacturing, over promising on clinical data (CagriSema), being slow-to-act in launching [direct-to-consumer], and a tepid initial response to compounders" ^[1]. BMO called the reorganization "a clear step in the right direction" but said Novo still needs to show "concrete results" ^[1].

Why it matters for patients

None of this changes the approved uses, labeling or availability of semaglutide products directly, and the sources do not report any supply disruption tied to the guidance cuts or the layoffs ^[1]. What the numbers do show is a company under real financial pressure in the exact market most GLP-1 patients live in.

Two details are worth watching. First, Novo says the savings will be "redirected to growth opportunities in diabetes and obesity," specifically commercial execution and R&D ^[1]. That is where pricing programs, direct-to-consumer channels and pipeline work sit. Second, BMO's critique names manufacturing underinvestment and a slow response to compounded copies as part of the problem ^[1] — both issues that have shaped what patients could actually get, and at what price, over the past two years.

How a leaner Novo behaves on list prices, cash-pay offerings and insurance negotiations is not addressed in the available sources. It is not yet known whether the restructuring will affect specific products, manufacturing sites or patient support programs.

What happens next

• Nov. 5, 2025: Novo Nordisk releases its third-quarter business report, which will include the 9 billion kroner in one-off restructuring charges ^[1].
• Fourth quarter 2025: The company expects about 1 billion kroner in offsetting savings to begin showing up ^[1].
• Through 2026: Novo targets roughly $1.25 billion in annualized savings from the job cuts ^[1].